Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

Table 3 Median reduction of headache days per month at different time intervals

	Weeks 8–12	FDR-adjusted P value	Weeks 20–24	FDR-adjusted P value	Weeks 44–48	FDR-adjusted P value
PP	8 [2–13]	< 0.001	9 [3–15]	< 0.001	10 [5–16]	< 0.001
ITT-BCF	7 [1–13]	< 0.001	7 [0–13]	< 0.001	7 [0–14]	< 0.001
ITT-LOCF	7 [1–13]	< 0.001	8 [0–14]	< 0.001	7 [0–14]	< 0.001

PP Per protocol, ITT Per intention-to-treat, BCF Baseline carried forward, LOCF, Last observation carried forward. Values in bold denotes statistical signification. FDR False discovery rate

ISSN: 1129-2377